Literature DB >> 18644851

Negative symptoms in schizophrenia: avolition and Occam's razor.

George Foussias1, Gary Remington.   

Abstract

The identification of schizophrenia's negative symptoms dates back to the earliest descriptions of Kraepelin and Bleuler, who each highlighted the central role of avolition in the phenomenology and course of this illness. Since, there have been numerous advances in our understanding of schizophrenia, and the present review tracks the changes that have taken place in our understanding of negative symptoms, their description and measurement. That these symptoms represent a distinct domain of the illness is discussed in the context of their ties to other symptoms and functional outcome. The underlying structure of the negative symptom construct is explored, including several lines of investigation that point towards diminished expression and amotivation as key underlying subdomains. We also discuss findings of intact emotional experience and consummatory pleasure in individuals with schizophrenia, calling into question the presence of anhedonia in this illness. We conclude with a reconceptualization of the negative symptoms, suggesting amotivation (ie, avolition) represents the critical component, particularly in regard to functional outcome. Further exploration and clarification of this core deficit will ultimately enhance our neurobiological understanding of schizophrenia, as well as strategies that may improve outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18644851      PMCID: PMC2833114          DOI: 10.1093/schbul/sbn094

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  73 in total

Review 1.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

3.  Emotional responding in deficit and non-deficit schizophrenia.

Authors:  K S Earnst; A M Kring
Journal:  Psychiatry Res       Date:  1999-11-29       Impact factor: 3.222

Review 4.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

5.  A standardized psychiatric assessment scale for rating chronic psychotic patients.

Authors:  M Krawiecka; D Goldberg; M Vaughan
Journal:  Acta Psychiatr Scand       Date:  1977-04       Impact factor: 6.392

6.  Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders.

Authors:  V Peralta; M J Cuesta
Journal:  Schizophr Res       Date:  1999-07-27       Impact factor: 4.939

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know.

Authors:  Deanna M Barch
Journal:  Schizophr Bull       Date:  2005-08-03       Impact factor: 9.306

9.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 10.  Apathy: a neuropsychiatric syndrome.

Authors:  R S Marin
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

View more
  147 in total

Review 1.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

2.  Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia.

Authors:  James A Waltz; Julie B Schweitzer; Thomas J Ross; Pradeep K Kurup; Betty J Salmeron; Emma J Rose; James M Gold; Elliot A Stein
Journal:  Neuropsychopharmacology       Date:  2010-08-18       Impact factor: 7.853

Review 3.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

4.  Probing the Dynamic Updating of Value in Schizophrenia Using a Sensory-Specific Satiety Paradigm.

Authors:  James A Waltz; Jaime K Brown; James M Gold; Thomas J Ross; Betty J Salmeron; Elliot A Stein
Journal:  Schizophr Bull       Date:  2015-04-01       Impact factor: 9.306

5.  The power to resist: the relationship between power, stigma, and negative symptoms in schizophrenia.

Authors:  Timothy R Campellone; Janelle M Caponigro; Ann M Kring
Journal:  Psychiatry Res       Date:  2013-11-26       Impact factor: 3.222

6.  Network Analysis Reveals Which Negative Symptom Domains Are Most Central in Schizophrenia vs Bipolar Disorder.

Authors:  Gregory Paul Strauss; Farnaz Zamani Esfahlani; Brian Kirkpatrick; Daniel N Allen; James M Gold; Katherine Frost Visser; Hiroki Sayama
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 7.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

8.  Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.

Authors:  Gregory P Strauss; William P Horan; Brian Kirkpatrick; Bernard A Fischer; William R Keller; Pinar Miski; Robert W Buchanan; Michael F Green; William T Carpenter
Journal:  J Psychiatr Res       Date:  2013-02-27       Impact factor: 4.791

9.  The processing of emotional stimuli during periods of limited attentional resources in schizophrenia.

Authors:  Gregory P Strauss; Lauren T Catalano; Katiah Llerena; James M Gold
Journal:  J Abnorm Psychol       Date:  2013-02-18

10.  Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.

Authors:  Tina Gupta; Henry R Cowan; Gregory P Strauss; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.